Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 132

recruiting
3 987
countries
28
conditions
2 109

1 824 trials match your criteria

Breast cancer metastatic

Not recruiting

Study of inavolisib, palbociclib and fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Fulvestrant

Anaemia+1

Not recruiting

Study of SEL120 Monohydrochloride for Treating Anemia in Patients with Lower-Risk Myelodysplastic Syndromes (MDS)

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:7,8-Dibromo-5,6-Dihydro-9-Methyl-2-(1-Piperazinyl)-4H-Imidazo[4,5,1-Ij]Quinoline Hydrochloride

Multiple sclerosis

Not recruiting

Study on Long-Term Safety and Efficacy of Ocrelizumab for Patients with Multiple Sclerosis

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Ocrelizumab

Myasthenia gravis

Not recruiting

Study on the Effectiveness and Safety of Batoclimab for Adults with Generalized Myasthenia Gravis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Batoclimab

Plasma cell myeloma+13

Not recruiting

Study on Atezolizumab and Drug Combinations for Advanced Malignancies in Patients from Previous Atezolizumab Trials

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Alectinib

Multiple sclerosis

Not recruiting

Study on the Effectiveness and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Children with Multiple Sclerosis

Registered drug
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Ofatumumab

Malignant melanoma stage III

Not recruiting

Study on Pembrolizumab for Patients with High-Risk Stage III Melanoma After Surgery

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab

Dry eye+1

Not recruiting

Study on the Effectiveness and Safety of Ianalumab for Patients with Active Sjögren’s Syndrome

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Ianalumab

Spinal muscular atrophy

Not recruiting

Study of Taldefgrobep Alfa for Patients with Spinal Muscular Atrophy on Stable Nusinersen and/or Risdiplam Regimen or with Onasemnogene Abeparvovec-xioi History

Investigational
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years
  • Substances:Taldefgrobep Alfa

Non-small cell lung cancer stage III

Not recruiting

Study of Atezolizumab and Tiragolumab Compared to Durvalumab for Patients with Advanced Non-Small Cell Lung Cancer After Chemoradiation

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab

Deafness neurosensory

Not recruiting

Study on the Effectiveness and Safety of AC102 Injection vs. Oral Prednisolone for Patients with Sudden Hearing Loss

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Prednisolone

HER2 positive breast cancer

Not recruiting

Study Comparing Trastuzumab Deruxtecan and Trastuzumab Emtansine for Patients with High-Risk HER2-Positive Breast Cancer with Residual Disease After Initial Treatment

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab Deruxtecan

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.